-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $42

Benzinga·12/23/2025 10:46:52
语音播报
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $34 to $42.